www.bioscience.co.uk
Sales & Support: +44 (0)1223 316 855

*

Anti-IL-17α (Ixekizumab), Humanized Antibody

Supplier:
Catalogue number:
A2149-100
Size:
100 µg
Product is available in:
  • UK
  • Ireland
  • Europe
  • USA
  • Rest of World
£581.00 Estimated delivery Wed 30 Jun
Shipping is calculated in checkout

The research-grade biosimilar is a humanised IgG4 monoclonal antibody that targets IL-17α and prevents the interaction with its receptor (IL-17R), thus blocking IL-17α mediated inflammatory and immune responses. IL-17α is known to play an important role in autoimmune diseases such as rheumatoid arthritis and plaque psoriasis. The monoclonal antibody is produced in CHO cells using recombinant DNA technology. It consists of two identical light chains of 219 amino acids each and two identical heavy chains of 445 amino acids each. The original drug was developed by Eli Lily and received approval from the FDA for the treatment of adults suffering from moderate-to-severe psoriasis and psoriatic arthritis

Product Type:

Antibodies

Species Reactivity:

Human

Storage Temp:

-80°C

Antibody Host:

Recombinant

Antibody Isotype:

IgG4, kappa

Formulation:

In PBS, pH 7.5

Antibody Type:

Monoclonal

UNSPSC Code:

12352203

Details Cat number & supplier Size Price
Anti-IL-4Rα (Dupilumab), Human IgG4 Antibody A2148-100 · BioVision
A2148-100
BioVision
100 µg £581.00
100 µg
view
Anti-TNFSF11 (Denosumab), Human IgG2 Antibody A2150-100 · BioVision
A2150-100
BioVision
100 µg £581.00
100 µg
view
Anti-IL-23α (Guselkumab), Human IgG1 Antibody A2147-100 · BioVision
A2147-100
BioVision
100 µg £581.00
100 µg
view
Anti-CD38 (Daratumumab), Human IgG1 Antibody A2151-100 · BioVision
A2151-100
BioVision
100 µg £581.00
100 µg
view
Anti-USP2 Antibody A2146-100 · BioVision
A2146-100
BioVision
100 µg £428.00
100 µg
view
Anti-PD-L1 (Avelumab), Human IgG1 Antibody A2152-100 · BioVision
A2152-100
BioVision
100 µg £581.00
100 µg
view
Anti-IgE (Omalizumab), Humanized Antibody A2145-100 · BioVision
A2145-100
BioVision
100 µg £530.00
100 µg
view